Resource data sheet
DNA Bank Top
Please review the QC test results indicated by check icon below as well as clone information before placing your order.

pENTER-EGFR Del19 (#RDB15489)

Gateway(R) entry vector of human epidermal growth factor receptor (EGFR), EGFR-activating mutation.

Clone info. Gateway(R) entry vector of human epidermal growth factor receptor (EGFR) mutant, deletion in exon 19, EGFR-activating mutation.
Comment cDNA was obtained from HCC-827 cells. Expression was confirmed by the depositor with western blotting after cloned into pLenti6.3 vector (by LR clonase II reaction). This clone contains a cDNA fragment corresponding to the 258nt to 3890nt of NM_005228.4. Known differences (at least) : C to T substitution at 731nt (N, synonym) ; 15nt (del19) deletion at 2493 to 2507nt ; G to A substitution at 2618nt (Q, synonym).
Vector backbone pENTR (plasmid)
Size of vector backbone 2.6 kb
Selectable markers Kan^r
Gene/insert name human EGFR cDNA
Depositor|Developer Katayama, Ryohei |
 

Distribution information

Please check terms and conditions set forth by the depositor, which are specified in the RIKEN BRC Catalog and/or Web Catalog.
Ordering forms
Order form [Credit Card Payment] [Bank Transfer Payment] [Example of order form ]
MTA, for use for not-for-profit academic purpose [Word] [Example of MTA ]
Please visit Information of Request for Distribution.[link] 
Terms and conditions for distribution In publishing the research results obtained by use of the BIOLOGICAL RESOURCE, a citation of literature designated by the DEPOSITOR is requested. (Uchibori, K et al. Nat. Commun. 8: 14768, 2017)
Remarks
Gateway® Entry clone. Please refer Life Technologies Corporation signs license agreement with RIKEN BRC.
提供案内 (日本国内) [open/close]

必要書類
提供依頼書  [依頼書の記入例 ]
提供同意書 (MTA, 非営利学術目的用)[Word] [MTAの記入例 ]
手続きの概要は、「提供申込みについて[link]」をご覧ください。
MTAに書く使用条件 利用者は、研究成果の公表にあたって寄託者の指定する文献を引用する(Uchibori, K et al. Nat. Commun. 8: 14768, 2017)。
備考
Gateway®テクノロジーを用いたエントリークローンです。「Gateway®テクノロジーを用いたクローンの提供と寄託のご案内」をご覧ください。

Catalog # Resource name Shipping form Fee (non-profit org.)
RDB15489 pENTER-EGFR Del19 DNA solution JPY 9,460 (not-for-profit academic purpose)
plus cost of shipping containers, dry ice (if required) and shipping charge

Please review the QC test results indicated by check icon below as well as clone information before placing your order.

How to cite this biological resource

Materials & Methods section:

The pENTER-EGFR Del19 was provided by the RIKEN BRC through the National BioResource Project of the MEXT, Japan (cat. RDB15489).

Reference section:

Uchibori, K., Inase, N., Araki, M., Kamada, M., Sato, S., Okuno, Y., Fujita, N., Katayama, R., Brigatinib combined with anti-EGFR antibody overcomes osimertinib resistance in EGFR-mutated non-small-cell lung cancer. Nat. Commun. 8: 14768 (2017). PMID 28287083. [link to RRC of NBRP]

Further references such as user reports and related articles (go to bottom)

QC test results

RIKEN BRC has sequenced portions of this material for quality test.
Please review the QC test results indicated by check icon as well as clone information before placing your order.

Test sheet RDB15489_A7K8p1-2.pdf check

Nucleotide sequence of a portion of this resource (if available).

Primer: rrnBT1ter_F2 (Pr0531)
Region: attL1, insert 5'
Sequence file: RDB15489_A7K8d.seq check
>D04925A2_A7K8_2_rrnBT1ter_F2_B04_04_ABI24.ab1
    1 NNNNNNNNNN NNNNNNNNNN NNNCCTTTCG TTTNNTTTGA NGCCTGGCAG TTCCCTACTC
   61 TCGCGTTAAC GCTAGCATGG ATGTTTTCCC AGTCACGACG TTGTAAAACG ACGGCCAGTC
  121 TTAAGCTCGG GCCCCAAATA ATGATTTTAT TTTGACTGAT AGTGACCTGT TCGTTGCAAC
  181 AAATTGATGA GCAATGCTTT TTTATAATGC CAACTTTGTA CAAAAAAGCA GGCTCCGCGG
  241 CCGCCCCCTT CACCATGCGA CCCTCCGGGA CGGCCGGGGC AGCGCTCCTG GCGCTGCTGG
  301 CTGCGCTCTG CCCGGCGAGT CGGGCTCTGG AGGAAAAGAA AGTTTGCCAA GGCACGAGTA
  361 ACAAGCTCAC GCAGTTGGGC ACTTTTGAAG ATCATTTTCT CAGCCTCCAG AGGATGTTCA
  421 ATAACTGTGA GGTGGTCCTT GGGAATTTGG AAATTACCTA TGTGCAGAGG AATTATGATC
  481 TTTCCTTCTT AAAGACCATC CAGGAGGTGG CTGGTTATGT CCTCATTGCC CTCAACACAG
  541 TGGAGCGAAT TCCTTTGGAA AACCTGCAGA TCATCAGAGG AAATATGTAC TACGAAAATT
  601 CCTATGCCTT AGCAGTCTTA TCTAACTATG ATGCAAATAA AACCGGACTG AAGGAGCTGC
  661 CCATGAGAAA TTTACAGGAA ATCCTGCATG GCGCCGTGCG GTTCAGCAAC AACCCTGCCC
  721 TGTGCAATGT GGAGAGCATC CAGTGGCGGG ACATAGTCAG CAGTGACTTT CTCAGCAACA
  781 TGTCGATGGA CTTCCNGANN CACCTNNGCA GCTGCCAAAA GTGTGATCCA AGCTGTCCCA
  841 ATGGGANCTG CTGGGGTGCA NGANANGANA NNTGCCAGAA ACTGANNAAA ATCATCTGNG
  901 CCCANCAGNG CTCCNGGNNC TGCCGNGGCA NNNCCCCCNA NNNNNNGCTN NCNNNACCAG
  961 NGNNCTGCNN NNNGCNNNNN NCCCNNNGGN NANCNNNNGN CNNNNNNNNN CNNNNAATNN
1021 CNNNNNNNAN NNNNNNNNN
//
Primer: pDONR_R (Pr0071)
Region: attL2, insert 3'
Sequence file: RDB15489_A7K8e.seq check
>D04925A2_A7K8_2_pDONR_R_B08_05_ABI24.ab1
    1 NNNNNNNNNN NGNNNNNCNN TGNNNNTGTA NTACGACTCN CTATAGGGGA NATCAGCTGG
   61 ATGGCAAATA ATGATTTTAT TTTGACTGAT AGTGACCTGT TCGTTGCAAC AAATTGATAA
  121 GCAATGCTTT CTTATAATGC CAACTTTGTA CAAGAAAGCT GGGTCGGCGC GCCCACCCTT
  181 TCATGCTCCA ATAAATTCAC TGCTTTGTGG CGCGACCCTT AGGTATTCTG CATTTTCAGC
  241 TGTGGAGCCC TTAAAGATGC CATTTGGCTT GGCTTCCTTG GGAAAGAAGT CCTGCTGGTA
  301 GTCAGGGTTG TCCAGGCTAA TTTGGTGGCT GCCTTTCTGG GCCCAGTGGG CAGGGCTGTC
  361 GAATGTGCTG TTGACACAGG TGGGCTGGAC AGTGTTGAGA TACTCGGGGT TGCCCACTGC
  421 AGTGCTGTGG GGGTCCTGGT AGTGTGGGTC TCTGCTGGGC GCGGGGTTCA GAGGCTGATT
  481 GTGATAGACA GGATTCTGCA CAGAGCCAGC GGGCCTTTTG GGAACGGACT GGTTTATGTA
  541 TTCAGGCACT GGGAGGAAGG TGTCGTCTAT GCTGTCCTCA GTCAAGGCGC CTGTGGGGTC
  601 TGAGCTGTAT CGCTGCAAGA AGCTGTCTTC CTTGATGGGA CAGCTTTGCA GCCCATTTCT
  661 ATCAATGCAA GCCACGGTGG AATTGTTGCT GGTTGCACTC AGAGAGCTCA NGANGGGAGT
  721 CCGTGACGTG GANGGGCTGC TGAAGAAGCC CTGCTGTGGG ANGANGTACT CGTCGGCATC
  781 CACCACGTCG TCCATGTCTT CTTCATCCAT CANGGCACGG TANAAGTTGG ANTCTGTANG
  841 ANTNNNCAAA TGCATTCTTT CNTCCCCCNN AANGACAAGG NANCGCNGGG GGNNCTCGGN
  901 NCATTTNNNA NAANNCNATG NTCNACTCNN NGNANNTTTG GNNNANTATC NNCNNNNNNN
961 NNN
//
Primer: EGFR-F5 (Pr0313)
Region: insert mid (del19)
Sequence file: RDB15489_A7K8f.seq check
>D04925A2_A7K8_2_EGFR-F5_B09_06_ABI24.ab1
    1 NNNNNNNNNN NNNNNNNNNN NNGGNNGGTG GGGGCCCTCC TCTTGCTGCT GGTGGTGGCC
   61 CTGGGGNTCG GCCTCTTCAT GCGAAGGCGC CACATCGTTC GGAAGCGCAC GCTGCGGAGG
  121 CTGCTGCAGG AGAGGGAGCT TGTGGAGCCT CTTACACCCA GTGGAGAAGC TCCCAACCAA
  181 GCTCTCTTGA GGATCTTGAA GGAAACTGAA TTCAAAAAGA TCAAAGTGCT GGGCTCCGGT
  241 GCGTTCGGCA CGGTGTATAA GGGACTCTGG ATCCCAGAAG GTGAGAAAGT TAAAATTCCC
  301 GTCGCTATCA AGACATCTCC GAAAGCCAAC AAGGAAATCC TCGATGAAGC CTACGTGATG
  361 GCCAGCGTGG ACAACCCCCA CGTGTGCCGC CTGCTGGGCA TCTGCCTCAC CTCCACCGTG
  421 CAACTCATCA CGCAGCTCAT GCCCTTCGGC TGCCTCCTGG ACTATGTCCG GGAACACAAA
  481 GACAATATTG GCTCCCAGTA CCTGCTCAAC TGGTGTGTGC AGATCGCAAA GGGCATGAAC
  541 TACTTGGAGG ACCGTCGCTT GGTGCACCGC GACCTGGCAG CCAGGAACGT ACTGGTGAAA
  601 ACACCGCAGC ATGTCAAGAT CACAGATTTT GGGCTGGCCA AACTGCTGGG TGCGGAAGAG
  661 AAAGAATACC ATGCAGAAGG AGGCAAAGTG CCTATCAAGT GGATGGCATT GGAATCAATT
  721 TTACACAGAA TCTATACCCA CCAGAGTGAT GTCTGGAGCT ACGGGGTGAN CGTTTGGGAG
  781 TTGANGACCT TTGGATCCNA GCCATATGAC GGANTCCCTG CCAGCGAGAT CTCCTCCATC
  841 CTGGANAAAG GANAANGCCT CCCTCANCCA CCCATATGTA CCATCNATGT CTACATGATC
  901 ATGGNCAAGN GCNNGNNGAN AGANNNANAN AGTCGNCCNA ANTNNCNNNA GTNNNTNATC
961 GNANTTCNNC NAAANNNNCN NNNNNCNNCN NNNNNNNNCN NNNNNNNNN
//

Please visit Sequencing and PCR primers for primer information.

References

Original, user report and related articles

original Uchibori, K., Brigatinib combined with anti-EGFR antibody overcomes osimertinib resistance in EGFR-mutated non-small-cell lung cancer. Nat. Commun. 8: 14768 (2017). PMID 28287083. [link to RRC of NBRP]